Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial - Reck, M; Mok, T SK; Nishio, M (The Lancet Respiratory Medicine, 2019)
et al.